Understanding potential risks and how we mitigate them is crucial for a trustworthy and transparent weight loss journey
Wegovy has been approved by the FDA to reduce risk of major adverse cardiovascular events (MACE) in those with a history of MACE, but studies of Zepbound are still pending
draw 1.20 mL total from the combined 2.0 mL and split into 2 injections at separate sites
As a medical treatment, it not only addresses sleep apnea but aids in weight loss, improves metabolic health, and thereby reduces related risks of high blood pressure, diabetes, food intake, and cholesterol
By enhancing insulin secretion and reducing appetite, it helps patients achieve significant weight loss while also improving overall metabolic health
Studies indicate that the metabolic profiles of individuals with depression often differ significantly from those of healthy controls